Guía para la práctica clínica | 02 FEB 20

Cribado del cáncer de próstata mediante el análisis del PSA

¿Cuál es el papel del cribado del antígeno prostático específico (PSA) en el cáncer de próstata?
Autor/a: Kari A O Tikkinen, Philipp Dahm, Lyubov Lytvyn, Anja F Heen y colaboradores BMJ 2018;362:k3581
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and metaanalysis. BMJ 2018;362:k3519. 10.1136/bmj.k3519.

2 Martin RM, Donovan JL, Turner EL, et al. CAP Trial Group. Effect of a lowintensity PSA-based screening intervention on prostate cancer mortality: The CAP Randomized Clinical Trial. JAMA 2018;319:883-95. 10.1001/jama.2018.0154 pmid:29509864.

3 Global Burden of Disease Cancer Collaboration. The Global burden of cancer 2013. JAMA Oncol 2015;1:505-27. 10.1001/jamaoncol.2015.0735. pmid:26181261.

4 Østerø Í Jákupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?BMJ 2018;361:k1202. 10.1136/bmj.k1202. pmid:29724877.

5 Schröder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. 10.1016/S0140-6736(14)60525-0. pmid:25108889.

6 Loeb S, Catalona WJ. Prostate-specific antigen screening: pro. Curr Opin Urol 2010;20:185-8. 10.1097/MOU.0b013e3283384047. pmid:20224413.

7 Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;(1):CD004720. 10.1002/14651858.CD004720.pub3. pmid:23440794.

8 Bell N, Connor Gorber S, Shane A, et al. Canadian Task Force on Preventive Health Care. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014;186:1225-34.10.1503/cmaj.140703. pmid:25349003.

9 Grossman DC, Curry SJ, Owens DK, et al. US Preventive Services Task Force. Screening for prostate cancer: Us preventive services task forcé recommendation statement. JAMA 2018;319:1901-13. 10.1001/jama.2018.3710. pmid:29801017.

10 Carroll PR, Parsons JK, Andriole G, et al. National comprehensive cancer network. Prostate cancer early detection, versión 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2014;12:1211-9, quiz 1219. 10.6004/jnccn.2014.0120 pmid:25190691.

11 Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190:419-26. 10.1016/j.juro.2013.04.119. pmid:23659877.

12 European Association of Urology. Mottet N, Bellmunt J, Briers E, et al. EAU – ESTRO – ESUR – SIOG Guidelines on prostate cancer. 2018. https://uroweb.org/guideline/prostate-cancer/.

13 Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524-48. 10.1001/jamaoncol.2016.5688. pmid:27918777.

14 Young GJ, Harrison S, Turner EL, et al. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. BMJ Open 2017;7:e017729. 10.1136/bmjopen-2017-017729. pmid:29084797.

15 Nordström T, Bratt O, Örtegren J, Aly M, Adolfsson J, Grönberg H. A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. Scand J Urol 2016;50:104-9.10.3109/21681805.2015.1113200. pmid:26625178.

16 Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054-61. 10.1001/jama.2015.14905. pmid:26575061.

17 Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416-23. 10.1200/JCO.2015.61.6532. pmid:26056181.

18 Van der Meer S, Kollen BJ, Hirdes WH, et al. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners. BJU Int 2013;112:26-31. 10.1111/bju.12029. pmid:23465178.

19 Drazer MW, Prasad SM, Huo D, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decisión making. Cancer 2014;120:1491-8. 10.1002/cncr.28600. pmid:24523016.

20 Misra-Hebert AD, Hu B, Klein EA, et al. Prostate cancer screening practices in a large, integrated health system: 2007-2014. BJU Int 2017;120:257-64. 10.1111/bju.13793. pmid:28139034.

21 Andriole GL, Crawford ED, Grubb RL 3rd, et al. PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32. 10.1093/jnci/djr500 pmid:22228146.

22 Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017;123:592-9. 10.1002/cncr.30474. pmid:27911486.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021